Tue, Apr 15, 8:57 PM (12 days ago)
**Eyenovia, Inc. (EYEN) - Summary** **Financial Performance (2024):** - **Revenue:** $57,336 - **Net Loss:** $49.8 million - **Cash and Cash Equivalents:** $2.1 million - **Working Capital Deficit:** $13.3 million - **Accumulated Deficit:** $195.3 million - **Research & Development Expenses:** $14.5 million - **Selling, General & Administrative Expenses:** $14.3 million **Strategic Overview:** - **Products:** Mydcombi® (FDA-approved), clobetasol propionate (FDA-approved), MicroPine (development halted) - **Technology:** Optejet® platform for topical ophthalmic medication dispensing - **Strategic Options:** Exploring business combinations, reverse mergers, asset sales to maximize shareholder value - **Manufacturing:** Expanded capabilities through partnerships and new facilities in Reno, NV, and Redwood City, CA **Future Outlook:** - **Optejet UFD:** Aiming for 510K submission in Q4 2025 - **Strategic Alternatives:** Evaluating full range of options, including business combinations, sales, reverse mergers, or asset sales - **Financial Condition:** Significant doubt about ability to continue as a going concern; exploring additional financing or strategic transactions **Risk Factors:** - **Financial Position:** Need for additional capital; reliance on strategic transactions - **Regulatory:** Dependence on FDA approvals; risk of delisting from Nasdaq - **Operational:** Dependence on key personnel; reliance on third-party manufacturers - **Intellectual Property:** Protection of patents and proprietary technology - **Market:** Competition; dependence on successful commercialization of products **Market Position Changes:** - **Nasdaq Listing:** Regained compliance with minimum bid price requirement - **Stock Performance:** Volatile; significant fluctuations due to market conditions and strategic developments **Amendment Details (if applicable):** - **Avenue Loan:** Deferred principal and interest payments until September 2025; potential conversion of up to $10 million into common stock - **Strategic Review:** Engaged Chardan as financial advisor to evaluate strategic alternatives **Note:** Amounts are usually in thousands, 000s.